NANicholas M. Allen

Nicholas M. Allen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas M. Allen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Amre Shahwan

    Department of Neurology and Clinical Neurophysiology Children’s Health Ireland at Temple Street Dublin Ireland

    1 shared publication
  • Bryan Lynch

    Department of Neurology and Clinical Neurophysiology Children’s Health Ireland at Temple Street Dublin Ireland

    1 shared publication
  • David Webb

    Department of Neurology and Clinical Neurophysiology Children’s Health Ireland at Crumlin Dublin Ireland

    1 shared publication
  • Declan O’rOurke

    Department of Neurology and Clinical Neurophysiology Children’s Health Ireland at Temple Street Dublin Ireland

    1 shared publication
  • Ireti Farombi-Oghuvbu

    Department of Neonatology, Rotunda Hospital, Dublin, Ireland

    1 shared publication
  • Irish Paediatric Neurology Group

    Members of the Irish Paediatric Neurology Group are listed in the Acknowledgements

    1 shared publication

Latest Publications

  • Open Access

    Response to treatment and outcomes of infantile spasms in Down syndrome

    by Susan Harvey, Nicholas M. Allen, Mary D. King, Bryan Lynch, Sally A. Lynch, Mary O’rEgan, Declan O’rOurke, Amre Shahwan, David Webb, Kathleen M. Gorman, et al.

    Aim: To estimate the prevalence, and evaluate presentation, treatment response, treatment side effects, and long‐term seizure outcomes in all known cases of children with Down syndrome and infantile spasms on the island of Ireland.Method: This was a 10‐year retrospective multicentre review of clinical records and investigations, focusing on treatment response, side effects, and long‐term outcomes.Results: The prevalence of infantile spasms in Down syndrome was 3.0% during the study period. Fifty‐four infants were identified with median age of spasm onset at 201 days (interquartile range [IQR] 156–242). Spasm cessation was achieved in 88% (n=46) at a median of 110 days (IQR 5–66). The most common first‐line medications were prednisolone (n=20, 37%), vigabatrin (n=18, 33.3%), and sodium valproate (n=9, 16.7%). At follow‐up (median age 23.7mo; IQR 13.4–40.6), 25% had ongoing seizures and 85% had developmental concerns. Treatment within 60 days did not correlate with spasm cessation. Seventeen children (31%) experienced medication side effects, with vigabatrin accounting for 52%.Interpretation: Prednisolone is an effective and well‐tolerated medication for treating infantile spasms in Down syndrome. Despite the high percentage of spasm cessation, developmental concerns and ongoing seizures were common.


  • Open Access

    Traumatic Delivery, Diaphragmatic Paresis, and “Dextrocardia”

    by Nicholas M. Allen, Tom Clarke, Stephanie P. Ryan, Ireti Farombi-Oghuvbu